ATE209908T1 - RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN - Google Patents

RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN

Info

Publication number
ATE209908T1
ATE209908T1 AT92914539T AT92914539T ATE209908T1 AT E209908 T1 ATE209908 T1 AT E209908T1 AT 92914539 T AT92914539 T AT 92914539T AT 92914539 T AT92914539 T AT 92914539T AT E209908 T1 ATE209908 T1 AT E209908T1
Authority
AT
Austria
Prior art keywords
disorders
derivatives
pbn
ischemia
spin
Prior art date
Application number
AT92914539T
Other languages
English (en)
Inventor
John M Carney
Robert A Floyd
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE209908T1 publication Critical patent/ATE209908T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92914539T 1991-06-18 1992-06-18 RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN ATE209908T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71695291A 1991-06-18 1991-06-18
PCT/US1992/005194 WO1992022290A1 (en) 1991-06-18 1992-06-18 Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins

Publications (1)

Publication Number Publication Date
ATE209908T1 true ATE209908T1 (de) 2001-12-15

Family

ID=24880110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92914539T ATE209908T1 (de) 1991-06-18 1992-06-18 RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN

Country Status (5)

Country Link
EP (1) EP0590072B1 (de)
AT (1) ATE209908T1 (de)
CA (1) CA2111836C (de)
DE (1) DE69232263T2 (de)
WO (1) WO1992022290A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681845A (en) * 1989-10-17 1997-10-28 Oklahoma Medical Research Foundation DMPO spin trapping compositions and methods of use thereof
JP3167763B2 (ja) 1991-11-07 2001-05-21 株式会社ユニエ 創傷治癒促進剤
US5455272A (en) * 1993-10-22 1995-10-03 Oklahoma Medical Research Foundation Spin trap nitronyl hindered phenols
US5405967A (en) * 1993-10-22 1995-04-11 Oklahoma Medical Research Foundation Spin-trap molecules 2-trifluoromethyl- of 5,5-dimethyl-1-dyrroline-N-oxide
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
DE9408805U1 (de) * 1994-05-30 1994-09-01 Baur, Albert, 86845 Großaitingen Lautsprecher, insbesondere in Säulenform
JPH0870889A (ja) * 1994-09-02 1996-03-19 Tokyo Jiyoshi Ika Univ 臓器障害誘導因子の検出方法
ES2239194T3 (es) * 1995-09-11 2005-09-16 Aventis Pharmaceuticals Inc. Nitronas ciclicas y composiciones farmaceuticas que las contienen.
TW450952B (en) * 1996-04-23 2001-08-21 Centaur Pharmaceuticals Inc Ophthalmic pharmaceutical compositions comprising a nitrone compound
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
WO1998003496A1 (en) * 1996-07-19 1998-01-29 Centaur Pharmaceuticals, Inc. Furan nitrone compounds
TW429241B (en) 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
US6046232A (en) * 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
WO1999036415A1 (en) * 1998-01-16 1999-07-22 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
ZA99255B (en) * 1998-01-16 1999-07-14 Centaur Pharmaceuticals Inc Thiopene nitrone compounds.
CA2323490A1 (en) * 1998-03-13 1999-09-16 Lowell D. Waterbury Inhibition of angiogenesis
US6083989A (en) 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
EP1077696A1 (de) * 1998-05-19 2001-02-28 Centaur Pharmaceuticals, Inc. Furan-nitrone therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
US6194465B1 (en) 1998-05-19 2001-02-27 Centaur Pharmaceuticals, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
SI1077694T1 (en) * 1998-05-19 2004-10-31 Renovis, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
RU2225392C2 (ru) * 1998-06-24 2004-03-10 Реновис, Инк. Альфа-арил-N-алкилнитроны, фармацевтические композиции (варианты), способ ингибирования нейродегенеративных заболеваний, способ лечения и способы профилактики (варианты)
FR2780404B1 (fr) * 1998-06-26 2001-04-13 Adir Nouveaux derives de nitrone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE267804T1 (de) 1998-07-17 2004-06-15 Renovis Inc Alpha-(2-hydroxyphenyl)nitrone, diese enthaltenden pharmazeutische zubereitungen sowie deren verwendung zur behandlung von entzündungen
AU1917301A (en) * 1999-11-18 2001-05-30 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics and methods for treating inflammatory bowel disease
US6835754B2 (en) 2001-01-08 2004-12-28 Renovis, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
EP1677745A4 (de) * 2003-10-14 2008-10-22 Renovis Inc Nitron-verbindungs-prodrugs und pharmazeutische zusammensetzung daraus zur behandlung von menschlichen erkrankungen
ES2349415T3 (es) * 2004-12-22 2011-01-03 Basf Se Agentes antiradicales.
DE602005022616D1 (de) 2004-12-22 2010-09-09 Basf Se Mittel gegen radikale
WO2007048645A2 (en) * 2005-10-24 2007-05-03 Ciba Holding Inc. Protection of oxidizable agents
FR2902097A1 (fr) * 2006-06-13 2007-12-14 Univ Joseph Fourier Etablissem Nouveau procede de preparation de nitrones et de n-hydroxylamines comportant au moins un groupe hydroxyle, et produits tels qu'obtenus
ES2529050T3 (es) 2006-07-25 2015-02-16 Hough Ear Institute Métodos para el tratamiento del trauma acústico agudo
CN104622879A (zh) 2008-02-12 2015-05-20 托斯克公司 减少毒性的多柔比星助剂及其使用方法
CN106061941B (zh) 2014-03-07 2018-05-08 陶氏环球技术有限责任公司 硝酮化合物及其在个人护理中的使用
WO2015175310A1 (en) 2014-05-12 2015-11-19 Dow Global Technologies Llc Nitrone compounds and their use in personal care
WO2016003767A1 (en) 2014-06-30 2016-01-07 Dow Global Technologies Llc Polymeric nitrones and their use in personal care
JP6734290B2 (ja) 2015-03-20 2020-08-05 ダウ グローバル テクノロジーズ エルエルシー 不飽和脂肪の酸化のニトロン抑制
US10137071B2 (en) 2015-03-20 2018-11-27 Dow Global Technologies Llc Nitrone inhibition of oxidation of unsaturated fats

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
WO1988005044A1 (en) * 1986-12-29 1988-07-14 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
AU1362488A (en) * 1987-01-28 1988-08-24 Peter H. Proctor Topical composition and method for stimulating hair growth with stable free radicals
HK1007281A1 (en) * 1989-10-17 1999-04-09 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration

Also Published As

Publication number Publication date
AU672364B2 (en) 1996-10-03
CA2111836C (en) 2006-08-29
EP0590072B1 (de) 2001-12-05
DE69232263D1 (de) 2002-01-17
EP0590072A1 (de) 1994-04-06
CA2111836A1 (en) 1992-12-23
WO1992022290A1 (en) 1992-12-23
DE69232263T2 (de) 2003-06-18
AU2261492A (en) 1993-01-12

Similar Documents

Publication Publication Date Title
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
BG101118A (en) Therapeutical compounds
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2&#39;- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
DE58904722D1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
NO801387L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive morfantridin-derivater
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DE69325512D1 (de) Verwendung von remacemid zur behandlung des morbus parkinson
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties